Niemann-Pick disease, type C and Roscoe Brady

Marc C. Patterson, Steven U. Walkley

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The Niemann-Pick family of diseases was poorly understood until Roscoe Brady and his colleagues began their investigations in the 1960s. Following Brady's discovery of the defect in acid sphingomyelinase in Niemann-Pick disease, types A and B, Peter Pentchev, a senior scientist in the group, launched a series of investigations of an unusual lipid storage disease in a spontaneous mouse model. These led initially to identification of the cholesterol trafficking defect in the mouse, and then in human Niemann-Pick disease, type C (NPC). This discovery formed the basis of the standard diagnostic test for NPC for the next three decades. Subsequently, an international collaboration was established, based at the Brady lab at NIH, which culminated in discovery of the NPC1 gene. Roscoe Brady, Peter Pentchev and their colleagues defined and refined the clinical biochemical and pathological phenotypes of NPC in a series of elegant parallel studies. They also identified abnormal oxysterols in NPC; later work has proved such compounds to be sensitive biomarkers of the disease. The dedication of the Brady lab to NPC, and the discoveries that flowed therefrom, provided critical foundations for the current explosion of progress in this disease.

Original languageEnglish (US)
Pages (from-to)34-37
Number of pages4
JournalMolecular Genetics and Metabolism
Volume120
Issue number1-2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Type C Niemann-Pick Disease
Type B Niemann-Pick Disease
Type A Niemann-Pick Disease
Niemann-Pick Diseases
Sphingomyelin Phosphodiesterase
Explosions
Genetic Association Studies
Anniversaries and Special Events
Routine Diagnostic Tests
Biomarkers
Cholesterol
Phenotype
Lipids
Defects
Acids
Identification (control systems)
Genes

Keywords

  • Biomarkers
  • Cholesterol
  • Cyclodextrin
  • Filipin
  • Gangliosides
  • Miglustat
  • Niemann-Pick disease
  • Oxysterols
  • Roscoe Brady
  • Type C

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Niemann-Pick disease, type C and Roscoe Brady. / Patterson, Marc C.; Walkley, Steven U.

In: Molecular Genetics and Metabolism, Vol. 120, No. 1-2, 01.01.2017, p. 34-37.

Research output: Contribution to journalReview article

@article{31ff2ec320914af09ac9bbcb9f1e6e0b,
title = "Niemann-Pick disease, type C and Roscoe Brady",
abstract = "The Niemann-Pick family of diseases was poorly understood until Roscoe Brady and his colleagues began their investigations in the 1960s. Following Brady's discovery of the defect in acid sphingomyelinase in Niemann-Pick disease, types A and B, Peter Pentchev, a senior scientist in the group, launched a series of investigations of an unusual lipid storage disease in a spontaneous mouse model. These led initially to identification of the cholesterol trafficking defect in the mouse, and then in human Niemann-Pick disease, type C (NPC). This discovery formed the basis of the standard diagnostic test for NPC for the next three decades. Subsequently, an international collaboration was established, based at the Brady lab at NIH, which culminated in discovery of the NPC1 gene. Roscoe Brady, Peter Pentchev and their colleagues defined and refined the clinical biochemical and pathological phenotypes of NPC in a series of elegant parallel studies. They also identified abnormal oxysterols in NPC; later work has proved such compounds to be sensitive biomarkers of the disease. The dedication of the Brady lab to NPC, and the discoveries that flowed therefrom, provided critical foundations for the current explosion of progress in this disease.",
keywords = "Biomarkers, Cholesterol, Cyclodextrin, Filipin, Gangliosides, Miglustat, Niemann-Pick disease, Oxysterols, Roscoe Brady, Type C",
author = "Patterson, {Marc C.} and Walkley, {Steven U.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ymgme.2016.11.008",
language = "English (US)",
volume = "120",
pages = "34--37",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Niemann-Pick disease, type C and Roscoe Brady

AU - Patterson, Marc C.

AU - Walkley, Steven U.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Niemann-Pick family of diseases was poorly understood until Roscoe Brady and his colleagues began their investigations in the 1960s. Following Brady's discovery of the defect in acid sphingomyelinase in Niemann-Pick disease, types A and B, Peter Pentchev, a senior scientist in the group, launched a series of investigations of an unusual lipid storage disease in a spontaneous mouse model. These led initially to identification of the cholesterol trafficking defect in the mouse, and then in human Niemann-Pick disease, type C (NPC). This discovery formed the basis of the standard diagnostic test for NPC for the next three decades. Subsequently, an international collaboration was established, based at the Brady lab at NIH, which culminated in discovery of the NPC1 gene. Roscoe Brady, Peter Pentchev and their colleagues defined and refined the clinical biochemical and pathological phenotypes of NPC in a series of elegant parallel studies. They also identified abnormal oxysterols in NPC; later work has proved such compounds to be sensitive biomarkers of the disease. The dedication of the Brady lab to NPC, and the discoveries that flowed therefrom, provided critical foundations for the current explosion of progress in this disease.

AB - The Niemann-Pick family of diseases was poorly understood until Roscoe Brady and his colleagues began their investigations in the 1960s. Following Brady's discovery of the defect in acid sphingomyelinase in Niemann-Pick disease, types A and B, Peter Pentchev, a senior scientist in the group, launched a series of investigations of an unusual lipid storage disease in a spontaneous mouse model. These led initially to identification of the cholesterol trafficking defect in the mouse, and then in human Niemann-Pick disease, type C (NPC). This discovery formed the basis of the standard diagnostic test for NPC for the next three decades. Subsequently, an international collaboration was established, based at the Brady lab at NIH, which culminated in discovery of the NPC1 gene. Roscoe Brady, Peter Pentchev and their colleagues defined and refined the clinical biochemical and pathological phenotypes of NPC in a series of elegant parallel studies. They also identified abnormal oxysterols in NPC; later work has proved such compounds to be sensitive biomarkers of the disease. The dedication of the Brady lab to NPC, and the discoveries that flowed therefrom, provided critical foundations for the current explosion of progress in this disease.

KW - Biomarkers

KW - Cholesterol

KW - Cyclodextrin

KW - Filipin

KW - Gangliosides

KW - Miglustat

KW - Niemann-Pick disease

KW - Oxysterols

KW - Roscoe Brady

KW - Type C

UR - http://www.scopus.com/inward/record.url?scp=85007444005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007444005&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2016.11.008

DO - 10.1016/j.ymgme.2016.11.008

M3 - Review article

VL - 120

SP - 34

EP - 37

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -